rilvegostomig (AZD2936) / Xoma, Compugen, AstraZeneca  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rilvegostomig (AZD2936) / AstraZeneca
TROPION-Lung10, NCT06357533: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Recruiting
3
675
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca, Daiichi Sankyo
Non-Small Cell Lung Cancer
04/28
05/30
DESTINY-BTC01, NCT06467357: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Not yet recruiting
3
620
Europe, Canada, Japan, RoW
Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, DS-8201a; T-DXd, Rilvegostomig, Agilent HercepTestâ„¢ mAb pharmDx, Ventana PD-L1 SP263 assay
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Biliary Tract Cancer
04/28
03/29
ARTEMIDE-Bil01, NCT06109779: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
AstraZeneca
Biliary Tract Cancer
06/29
09/30

Download Options